Robert Mulroy

Chief Executive Officer

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Debasish Roychowdhury, MD

Chief Technology Officer

Debasish serves as a director and the Chief Technology Officer of PTx. Debasish is a medical oncologist and a proven leader in the pharmaceutical industry with over 15 years of industry senior management experience and 14 years of patient care, academic research and teaching experience. Prior to PTx, he served as the Chief Medical Officer of Seragon through the company’s acquisition by Roche. Prior to Seragon, Debasish served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. Debasish is a member of the Board of Directors for Radius Health, Celyad, Lytix Biopharma AS and Fund+.

Sarah Kurz

Executive Vice President

As the Executive Vice President of PTx, Sarah chairs the company’s Executive Leadership Team and leads the Commercial and Medical Affairs functions.  Prior to joining PTx, Sarah served as Vice President of Sales and Operations at Merrimack Pharmaceuticals where she built the company’s commercial infrastructure and launched the company’s first commercial product in pancreatic cancer.  At Ipsen Biopharmaceuticals, Sarah oversaw the company’s neurology and endocrinology product portfolios, served as a member of the North American Executive Team, and led the restructuring of Ipsen’s U.S. business.  Prior to that, Sarah oversaw MacroGenics’ global late-stage development program in juvenile diabetes and managed the company’s global alliance with Eli Lilly.  She holds an undergraduate degree from Bowdoin College and both an MBA and MPH from Emory University.

Bill McClements

Chief Financial and Operations Officer

Bill serves as PTx’s Chief Financial and Operations Officer. For over twenty years, Bill helped to lead and build the Monitor Group, a global strategic advisory firm, where he served as a Partner, Executive Committee member and Chief Operating Officer. Prior to PTx, he served as Senior Vice President of Corporate Operations at Merrimack Pharmaceuticals. Bill holds an MBA from Harvard Business School and a BA from Williams College.

Dave Carlson

Vice President Manufacturing

Dave serves as the head of manufacturing for PTx. He has 30 years of biologic manufacturing experience. Most recently, Dave served as the site head under Sanofi for the Northpointe manufacturing facility in Lynnwood, Washington. He held similar management posts under Genzyme, Bayer, and Berlex overseeing manufacturing operations. Dave started his career with Immunex and holds BS in microbiology from Oregon State University.

John McManus

Chief Business Officer

John serves as PTx’s Chief Business Officer. He has 20 years of leadership experience in the biopharmaceutical industry, that includes leading the transformation of several biotech companies through strategic partnerships and execution of value based strategies. Prior to joining PTx, John was the CEO of Aeolus Pharmaceuticals, where he managed a $100+ million BARDA contract for the advanced development of a radiation medical countermeasure. Before joining Aeolus, John served in strategic and financial roles at Spectrum Pharmaceuticals where he focused on oncology and NeoTherapeutics where he focused on Alzheimer’s, Parkinson’s, ALS and spinal cord injury. John holds a B.S. in International Finance and Business Economics from the University of Southern California.

Lisa Rutter

Executive Director & Head of Quality

Lisa Rutter is the Executive Director, Head of Quality at Partner Therapeutics, a position she has held since 2017.  Lisa previously held positions with Sanofi as Associate Director of Quality Control and Quality Systems Manager. She managed and was responsible for testing related to the manufacturing and release of Leukine, testing and release of raw materials, microbiological control of the utility systems and the manufacturing environment, program/system management of Deviation/CAPA, Change Control, Training and Document Management.

Prior to Sanofi, Lisa worked for Dendreon, Genentech, Amgen, and a contract research organization where she performed analytical method development, managed product testing laboratories conducting analytical release and stability testing of biological products and the implementation and administration of quality systems.

Lisa has a Bachelor’s Degree in Biology from Washington State University and brings 30 years of experience in biopharmaceuticals, including testing of clinical and commercial products and the development and management of Quality Systems with a focus on operational efficiencies using six sigma techniques and tools.